© PCG Advisory, 2020. All Rights Reserved.
Lexaria has patented and commercialized the world’s newest innovative drug delivery technology (DehydraTECH™) that has been both laboratory and market proven to enhance the performance of several categories of drugs, always in oral and/or topical product formats.
Lexaria’s technology is easily applied through incorporation of an intermediate step in the formulation and manufacturing of existing or new orally-ingestible and topical products. This step involves mixing the active ingredient or drug as a delivery “payload” together with certain fatty acids, infusing the mixture into a substrate material, and then using controlled dehydration synthesis processing to conjugate the payload and fatty acids together at a molecular level before integrating the newly-combined molecules into production.
DehydraTECH™ Delivers Better Pharmaceutical Absorption Rates
Lexaria is changing the way Active Pharmaceutical Ingredients (APIs) are absorbed into the bloodstream with its groundbreaking DehydraTECH™ technology. This highly anticipated drug delivery technology comes with diverse application opportunities and is already turning heads from companies in major industries like cannabis and hemp, nicotine, and NSAIDs.
DehydraTECH™ allows subjects to feel the drug’s effects within minutes rather than having to wait as long as two hours. Unwanted side effects are also mitigated by the avoidance of first-pass liver metabolism and both bio-absorption and brain permeation increase exponentially.
Lexaria Bioscience is a client of PCG Advisory, Inc., an investor relations and communications firm. Please see our disclosures on our website www.pcgadvisory.com.
Lexaria Bioscience Advances 2021 Strategic Initiatives
Clinical Findings Reveal Opportunity in Multi-Billion Dollar Cannabinoid Industry
Lexaria’s role in the cannabis industry is similarly growing at a fast rate. To date, eight companies have licensed DehydraTECH™ for its oral delivery capabilities. This arm of Lexaria’s technology implementation is largely due to a 2018 study that confirmed DehydraTECH™’s superior effectiveness in cannabinoid absorption into blood plasma using a 90 mg dose of Lexaria’s TurboCBD™.
Specifically, the results revealed that the volunteers had 317% more CBD in their bloodstreams at the 30-minute mark, with a significantly higher peak blood concentration compared to participants with either a placebo or a traditional 90 mg dose of CBD. Participants using the TurboCBD™ oral formulation tested in that study also experienced lower blood pressure and higher brain perfusion.
Lexaria recently announced its approval from a European university research hospital’s ethics board to conduct a more in-depth exploratory clinical study. The study will explore the impact of CBD paired with DehydraTECH™ on participants’ blood pressure levels, which could eventually lead to exciting pharmaceutical applications related to blood pressure medications, subject to further study.